Etanercept in the treatment of rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 13, Issue 10, 2013, Pages 1441-1450

  Hunt, Laura ^a   Emery, Paul ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Biologic agents; Etanercept; Randomised control trials; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; CD20 ANTIGEN; CELL SURFACE RECEPTOR; CERTOLIZUMAB PEGOL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; GOLIMUMAB; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL THERAPY; CANCER RISK; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; LYMPHOMA; MELANOMA; META ANALYSIS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SOFT TISSUE INFECTION; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84884223659     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.823154     Document Type: Article

References (95)

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(2Suppl1):1-12
2. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32(1):9-44
3. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69(4):631-7
4. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: Evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54(12):3761-73
5. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1):26-37
6. van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercePTand methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56(12):3928-39
7. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - adalimumab, etanercePTand infliximab: Guidance [TA130]. London 2007
8. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34(9):1125-32
9. Saxne T, Palladino MA Jr., Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31(8):1041-5
10. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35(10):1160-9
11. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151(3):1548-61
12. Zhou SY, Shu C, Korth-Bradley J, et al. Integrated population pharmacokinetics of etanercePTin healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol 2011;51(6):864-75
13. Zhou H. Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005;45(5):490-7
14. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercePTin healthy volunteers. Ann Pharmacother 2000;34(2):161-4
15. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercePTin patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50(2):353-63
16. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercePTin psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152(6):1304-12
17. Leonardi CL, Powers JL, Matheson RT, et al. EtanercePTas monotherapy in patients with psoriasis. N Engl J Med 2003;349(21):2014-22
18. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercePT50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercePT50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008;58(7):1921-30
19. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercePTobtain lower etanercePTconcentrations compared with responding patients. Ann Rheum Dis 2012;71(1):88-91
20. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337(3):141-7
21. Moreland LW, Schiff MH, Baumgartner SW, et al. EtanercePTtherapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
22. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9
23. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercePTand methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363(9410):675-81
24. van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercePTand methotrexate for rheumatoid arthritis: The TEMPO trial. Ann Rheum Dis 2006;65(3):328-34
25. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercePTand methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54(4):1063-74
26. van der Heijde D, Burmester G, Melo-Gomes J, et al. Inhibition of radiographic progression with combination etanercePTand methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis 2009;68(7):1113-18
27. Combe B, Codreanu C, Fiocco U, et al. EtanercePTand sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: A double-blind comparison. Ann Rheum Dis 2006;65(10):1357-62
28. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercePTand methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93
29. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercePTin active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 2008;372(9636):375-82
30. Genovese MC, Bathon JM, Martin RW, et al. EtanercePTversus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46(6):1443-50
31. Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercePTplus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. Ann Rheum Dis 2010;69(1):222-5
32. Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. Arthritis Rheum 2010;62(3):674-82
33. Emery P, Kvien TK, Combe B, et al. Combination etanercePTand methotrexate provides better disease control in very early (< = 4 months) versus early rheumatoid arthritis (> 4 months and < 2 years): Post hoc analyses from the COMET study. Ann Rheum Dis 2012;71(6):989-92
34. Emery P, Hamoudeh M, FitzGerald OM, et al. Induction of Remission in Patients with up to 12 months of moderate-to-severe Rheumatoid Arthritis Symptoms treated with EtanercePTPlus Methotrexate Over 52 Weeks [abstract]. Arthritis Rheum 2012;64(Suppl10):2549
35. Villeneuve E, Nam JL, Hensor E, et al. Preliminary Results of a Multicentre Randomised Control Trials of EtanercePTand Methotrexate to Induce Remission in Patients with Newly Diagnosed Inflammatory Arthritis [abstract]. Arthritis Rheum 2011;63:Suppl10
36. Moreland LW, O'Dell JR., Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercePTplus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64(9):2824-35
37. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363(4):301-4
38. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercePTafter treatment with etanercePTand methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet 2013;381(9870):918-29
39. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54(3):692-701
40. Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercePTwith reference to disease-modifying anti-rheumatic drugs: Long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 2013; In press
41. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: Anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63(4):522-9
42. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66(5):670-5
43. Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercePTbeyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res 2011;63(3):373-82
44. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 2007;56(9):2896-904
45. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52(11):3403-12
46. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49(11):2217-19
47. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50(1):124-31
48. Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013;72(2):229-34
49. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercePTin a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29(2):238-47
50. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2(6):561-72
51. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34(4):706-11
52. Fonseca JE, Canhao H, Silva C, et al. [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: The Portuguese experience]. Acta Reumatol Port 2006;31(3):247-53
53. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50(2):372-9
54. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52(7):1986-92
55. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003;48(8):2122-7
56. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69(3):522-8
57. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60(7):1884-94
58. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301(2):418-26
59. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010;10(3):308-15
60. Sandborn WJ, Hanauer SB, Katz S, et al. EtanercePTfor active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121(5):1088-94
61. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercePTfor treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62(1):74-6
62. Utz JP, Limper AH, Kalra S, et al. EtanercePTfor the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124(1):177-85
63. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial. Eur Respir J 2008;31(6):1189-96
64. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174(7):795-802
65. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012;142(5):1102-11
66. Lofberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE. Inflamm Bowel Dis 2012;18(1):1-9
67. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Jama 2009;301(7):737-44
68. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57(8):1431-8
69. McDonald JR., Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009;48(10):1364-71
70. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006;45(11):1370-5
71. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006;45(10):1294-7
72. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: Case reports. Clin Rheumatol 2008;27(8):1069-71
73. Peterson JR., Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62(11):1078-82
74. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66(7):880-5
75. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64(5):699-703
76. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007;56(9):2886-95
77. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68(5):648-53
78. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71(6):869-74
79. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32(11):2130-5
80. Mercer LK, Galloway J.B, Lunt M, et al. The influence of anti-TNF therapy upon incidence of non-melanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA): Results from the BSR Biologics Register (BSRBR) [abstract]. Arthritis & Rheumatism 2009;60(S10):772
81. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis 2011;70(11):1895-904
82. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercePTliquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(1):40-6
83. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;16:2
84. Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: An appraisal of predictors. J Rheumatol 2012;39(6):1179-84
85. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62(1):22-32
86. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009
87. Du Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61(5):560-8
88. Sakai R, Tanaka M, Nanki T, et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012;71(11):1820-6
89. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis 2012. [Epub ahead of print
90. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(3):711-15
91. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66(7):921-6
92. Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with etanercePTtreatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;64(12):3850-5
93. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercePTin patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(4):531-5
94. Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011;332(6028):478-84
95. Bayry J. New horizons in natural TNF-alpha antagonist research. Trends Mol Med 2011;17(10):538-40